|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACHE |
Gene summary for ACHE |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACHE | Gene ID | 43 |
| Gene name | acetylcholinesterase (Cartwright blood group) | |
| Gene Alias | ACEE | |
| Cytomap | 7q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | P22303 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 43 | ACHE | LZE4T | Human | Esophagus | ESCC | 6.35e-03 | 1.38e-01 | 0.0811 |
| 43 | ACHE | LZE24T | Human | Esophagus | ESCC | 1.80e-03 | 1.88e-01 | 0.0596 |
| 43 | ACHE | P2T-E | Human | Esophagus | ESCC | 1.75e-25 | 4.93e-01 | 0.1177 |
| 43 | ACHE | P8T-E | Human | Esophagus | ESCC | 3.97e-04 | 1.41e-01 | 0.0889 |
| 43 | ACHE | P11T-E | Human | Esophagus | ESCC | 1.06e-12 | 5.35e-01 | 0.1426 |
| 43 | ACHE | P12T-E | Human | Esophagus | ESCC | 1.66e-02 | 9.56e-02 | 0.1122 |
| 43 | ACHE | P16T-E | Human | Esophagus | ESCC | 1.46e-28 | 4.61e-01 | 0.1153 |
| 43 | ACHE | P23T-E | Human | Esophagus | ESCC | 3.88e-04 | 3.53e-01 | 0.108 |
| 43 | ACHE | P28T-E | Human | Esophagus | ESCC | 1.78e-03 | 1.20e-01 | 0.1149 |
| 43 | ACHE | P36T-E | Human | Esophagus | ESCC | 7.72e-03 | 2.14e-01 | 0.1187 |
| 43 | ACHE | P39T-E | Human | Esophagus | ESCC | 1.78e-03 | 1.10e-01 | 0.0894 |
| 43 | ACHE | P47T-E | Human | Esophagus | ESCC | 8.84e-05 | 1.57e-01 | 0.1067 |
| 43 | ACHE | P57T-E | Human | Esophagus | ESCC | 3.50e-02 | 8.07e-02 | 0.0926 |
| 43 | ACHE | P62T-E | Human | Esophagus | ESCC | 5.58e-03 | 3.36e-01 | 0.1302 |
| 43 | ACHE | P65T-E | Human | Esophagus | ESCC | 7.69e-05 | 1.42e-01 | 0.0978 |
| 43 | ACHE | P74T-E | Human | Esophagus | ESCC | 2.03e-13 | 3.45e-01 | 0.1479 |
| 43 | ACHE | P75T-E | Human | Esophagus | ESCC | 4.17e-05 | 1.74e-01 | 0.1125 |
| 43 | ACHE | P76T-E | Human | Esophagus | ESCC | 2.86e-20 | 4.18e-01 | 0.1207 |
| 43 | ACHE | P79T-E | Human | Esophagus | ESCC | 2.86e-20 | 4.42e-01 | 0.1154 |
| 43 | ACHE | P82T-E | Human | Esophagus | ESCC | 5.95e-17 | 1.38e+00 | 0.1072 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1904951111 | Esophagus | ESCC | positive regulation of establishment of protein localization | 216/8552 | 319/18723 | 1.01e-15 | 6.86e-14 | 216 |
| GO:0051222111 | Esophagus | ESCC | positive regulation of protein transport | 204/8552 | 303/18723 | 1.56e-14 | 8.38e-13 | 204 |
| GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
| GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
| GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
| GO:000164918 | Esophagus | ESCC | osteoblast differentiation | 140/8552 | 229/18723 | 1.63e-06 | 1.95e-05 | 140 |
| GO:000150317 | Esophagus | ESCC | ossification | 232/8552 | 408/18723 | 3.00e-06 | 3.40e-05 | 232 |
| GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
| GO:004311218 | Esophagus | ESCC | receptor metabolic process | 104/8552 | 166/18723 | 7.44e-06 | 7.37e-05 | 104 |
| GO:00066561 | Esophagus | ESCC | phosphatidylcholine biosynthetic process | 24/8552 | 29/18723 | 4.50e-05 | 3.55e-04 | 24 |
| GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
| GO:000689818 | Esophagus | ESCC | receptor-mediated endocytosis | 142/8552 | 244/18723 | 5.22e-05 | 4.05e-04 | 142 |
| GO:003432918 | Esophagus | ESCC | cell junction assembly | 227/8552 | 420/18723 | 3.06e-04 | 1.83e-03 | 227 |
| GO:00019192 | Esophagus | ESCC | regulation of receptor recycling | 19/8552 | 23/18723 | 3.12e-04 | 1.85e-03 | 19 |
| GO:00018813 | Esophagus | ESCC | receptor recycling | 25/8552 | 33/18723 | 4.30e-04 | 2.43e-03 | 25 |
| GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
| GO:000930617 | Esophagus | ESCC | protein secretion | 190/8552 | 359/18723 | 3.22e-03 | 1.34e-02 | 190 |
| GO:003559217 | Esophagus | ESCC | establishment of protein localization to extracellular region | 190/8552 | 360/18723 | 3.77e-03 | 1.53e-02 | 190 |
| GO:007169210 | Esophagus | ESCC | protein localization to extracellular region | 193/8552 | 368/18723 | 5.01e-03 | 1.92e-02 | 193 |
| GO:01201624 | Esophagus | ESCC | positive regulation of cold-induced thermogenesis | 57/8552 | 97/18723 | 6.43e-03 | 2.35e-02 | 57 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACHE | SNV | Missense_Mutation | novel | c.889G>T | p.Asp297Tyr | p.D297Y | P22303 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| ACHE | SNV | Missense_Mutation | c.1243N>A | p.Asp415Asn | p.D415N | P22303 | protein_coding | tolerated(0.06) | probably_damaging(0.997) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ACHE | SNV | Missense_Mutation | c.323A>G | p.Tyr108Cys | p.Y108C | P22303 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| ACHE | SNV | Missense_Mutation | novel | c.1427N>G | p.Val476Gly | p.V476G | P22303 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-E9-A22A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| ACHE | insertion | In_Frame_Ins | novel | c.146_147insTAAAATGGGATCGCTAGTGGAAATGAGGTGGGA | p.Arg49_Gly50insLysMetGlySerLeuValGluMetArgTrpGlu | p.R49_G50insKMGSLVEMRWE | P22303 | protein_coding | TCGA-AO-A0JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| ACHE | SNV | Missense_Mutation | novel | c.64C>A | p.Leu22Ile | p.L22I | P22303 | protein_coding | tolerated(0.24) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ACHE | SNV | Missense_Mutation | novel | c.1495G>C | p.Glu499Gln | p.E499Q | P22303 | protein_coding | tolerated(0.16) | benign(0.017) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| ACHE | SNV | Missense_Mutation | c.1348G>A | p.Ala450Thr | p.A450T | P22303 | protein_coding | tolerated(0.07) | benign(0.209) | TCGA-EA-A5ZF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| ACHE | SNV | Missense_Mutation | novel | c.373N>C | p.Glu125Gln | p.E125Q | P22303 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ACHE | SNV | Missense_Mutation | rs780793869 | c.247C>T | p.Pro83Ser | p.P83S | P22303 | protein_coding | tolerated(0.06) | probably_damaging(0.997) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 43 | ACHE | ENZYME, CELL SURFACE, DRUGGABLE GENOME | 4-PAM derivative 1 | |||
| 43 | ACHE | ENZYME, CELL SURFACE, DRUGGABLE GENOME | Edrophonium | EDROPHONIUM | ||
| 43 | ACHE | ENZYME, CELL SURFACE, DRUGGABLE GENOME | Rivastigmine | RIVASTIGMINE | ||
| 43 | ACHE | ENZYME, CELL SURFACE, DRUGGABLE GENOME | RIVASTIGMINE | RIVASTIGMINE | ||
| 43 | ACHE | ENZYME, CELL SURFACE, DRUGGABLE GENOME | PMID29757691-Compound-7 | |||
| 43 | ACHE | ENZYME, CELL SURFACE, DRUGGABLE GENOME | inhibitor | CHEMBL1025 | ISOFLUROPHATE | |
| 43 | ACHE | ENZYME, CELL SURFACE, DRUGGABLE GENOME | ACOTIAMIDE | ACOTIAMIDE | ||
| 43 | ACHE | ENZYME, CELL SURFACE, DRUGGABLE GENOME | inhibitor | 310264771 | NEOSTIGMINE | |
| 43 | ACHE | ENZYME, CELL SURFACE, DRUGGABLE GENOME | PHYSOSTIGMINE | PHYSOSTIGMINE | ||
| 43 | ACHE | ENZYME, CELL SURFACE, DRUGGABLE GENOME | TURBINATINE | TURBINATINE | 15568781 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |